Cargando…
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
INTRODUCTION: Recent studies have suggested that including presence or absence of ground-glass opacity (GGO) may improve the tumor descriptor (T descriptor) classification in clinical stage I NSCLC. In this study, we analyzed prognostic implications of presence or absence of GGO, size of the solid c...
Autores principales: | Hamada, Akira, Suda, Kenichi, Fujino, Toshio, Nishino, Masaya, Ohara, Shuta, Koga, Takamasa, Kabasawa, Takanobu, Chiba, Masato, Shimoji, Masaki, Endoh, Makoto, Takemoto, Toshiki, Soh, Junichi, Yanagawa, Naoki, Shiono, Satoshi, Mitsudomi, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097453/ https://www.ncbi.nlm.nih.gov/pubmed/35574192 http://dx.doi.org/10.1016/j.jtocrr.2022.100321 |
Ejemplares similares
-
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022) -
Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study
por: Ohara, Shuta, et al.
Publicado: (2020) -
Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis
por: Ohara, Shuta, et al.
Publicado: (2019) -
Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
por: Koga, Takamasa, et al.
Publicado: (2023) -
Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
por: Koga, Takamasa, et al.
Publicado: (2021)